AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23293276
Drug: Intraperitoneal nebulization
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal nebulization of ropivacaine 1% (3 ml) before surgical dissection and normal saline 3 ml at the end of surgery (preoperative nebulization group)
Trial: 23293276
Drug: Intraperitoneal nebulization
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal nebulization of normal saline 3 ml before surgical dissection and ropivacaine 1% (3 ml) at the end of surgery (postoperative nebulization group)
Trial: 23293276
Drug: Intraperitoneal nebulization
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal nebulization of normal saline 3 ml before surgical dissection and at the end of surgery (placebo group)
Trial: 19376305
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy for 6 months
Trial: 19376305
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy for 12 months
Trial: 17214931
Drug: Ruyi Dingchuan
RxNorm normalized name: BENZALKONIUM CHLORIDE 0.148 g in 100 mL TOPICAL SPRAY [Jingchuang Chonggao Disinfectant]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruyi Dingchuan Pill
Trial: 4015075
Drug: Moxalactam (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxalactam (4 g intravenously every 12 h)
Trial: 4015075
Drug: Temocillin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temocillin (4 g intravenously every 12 h)
Trial: 21313926
Drug: Closed and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed and totally hyaluronan based heparin free coated ECC
Trial: 21313926
Drug: Open, totally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open, totally hyaluronan based heparin free coated ECC
Trial: 12161496
Drug: Gas chromatography/mass
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gas chromatography/mass spectrometry method for simultaneous measurement of 15 urinary steroid metabolites
Trial: 10341861
Drug: rIFN-alpha +
RxNorm normalized name: rIFN-alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rIFN-alpha + iodine (10 drops SSKI, approximately 350 mg iodine daily)
Trial: 10341861
Drug: Iodine alone
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodine alone (10 drops SSKI, approximately 350 mg iodine daily)
Trial: 6997111
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release form of amitriptyline (Lentizol) 50 mg (doubled after 1 week)
Trial: 6997111
Drug: Dothiepin (Prothiaden)
RxNorm normalized name: dothiepin
DrugBank: Dosulepin (DB09167)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dothiepin (Prothiaden) 75 mg (doubled after 1 week)
Trial: 28391657
Drug: apremilast 20
RxNorm normalized name: apremilast 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: apremilast 20 mg b.i.d.
Trial: 22958974
Drug: Glycerol phenylbutyrate
RxNorm normalized name: Glycerol Phenylbutyrate
DrugBank: Glycerol phenylbutyrate (DB08909)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Glycerol phenylbutyrate (1.5 to 31.8 g/day)
Trial: 22958974
Drug: Sodium phenylbutyrate
RxNorm normalized name: Sodium Phenylbutyrate
DrugBank: Phenylbutyric acid (DB06819)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium phenylbutyrate (1.3 to 31.7 g/day)
Trial: 17523342
Drug: Omeprazole (OPZ)
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole (OPZ) 20 mg/day + AMPC 1500 mg/day + CAM 600 mg/day (OAC)
Trial: 17523342
Drug: Lansoprazole (LPZ)
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole (LPZ) 30 mg + AMPC 1500 mg/day + CAM 600 mg/day (LAC)
Trial: 17523342
Drug: Rabeprazole (RPZ)
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rabeprazole (RPZ) 10 mg/day + AMPC 1500 mg/day + CAM 600 mg/day (RAC)
Trial: 15693450
Drug: 1 week
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 week of triple therapy (omeprazole 20 mg, clarithromycin 250 mg, tinidazole 500 mg)
Trial: 15693450
Drug: 2 weeks
RxNorm normalized name: Rykindo, 25 mg/2 weeks intramuscular powder for injection, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 weeks of triple therapy (omeprazole 20 mg, clarithromycin 250 mg, tinidazole 500 mg)
Trial: 15693450
Drug: 1 week
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 week of triple therapy
Trial: 15693450
Drug: 2 weeks
RxNorm normalized name: Rykindo, 25 mg/2 weeks intramuscular powder for injection, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 weeks of triple therapy
Trial: 1901638
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate depot, 3.75 mg intramuscularly every 4 weeks for 24 weeks
Trial: 25847559
Drug: 1mg/kg Ginkgo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1mg/kg Ginkgo biloba extract (G group n=30)
Trial: 7559260
Drug: Zaditen SRO
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zaditen SRO 4 mg once daily
Trial: 7559260
Drug: Zaditen SRO
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zaditen SRO 2 mg once daily
Trial: 7559260
Drug: Zaditen Standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zaditen Standard Form 1 mg twice daily
Trial: 2196774
Drug: Intravenous captopril
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous captopril (n = 8)
Trial: 3653591
Drug: Nifedipine 60
RxNorm normalized name: nifedipine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 60 mg/day
Trial: 7025625
Drug: Propranolol 280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 280 mg/day
Trial: 1732370
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Nifedipine and Propranolol
Trial: 29199100
Drug: Universal antiretroviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Universal antiretroviral therapy (ART) with fixed-dose combination of tenofovir, emtricitabine, and efavirenz, regardless of CD4 cell count.
Trial: 24395288
Drug: Calcium and
RxNorm normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium and cholecalciferol supplementation (1,000 mg/day calcium and 800 IU cholecalciferol)
Trial: 29654643
Drug: Sitagliptin 25
RxNorm normalized name: SITagliptin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 25 mg
Trial: 17156104
Drug: Sitagliptin (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin (all doses)
Trial: 2883488
Drug: Doxycycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (100 mg daily)
Trial: 30892987
Drug: Encorafenib 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encorafenib 300 mg daily, binimetinib 45 mg twice daily, plus standard weekly cetuximab
Trial: 21874538
Drug: Pitavastatin 4
RxNorm normalized name: PITAVASTATIN 4MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitavastatin 4 mg
Trial: 21812889
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 or 40 mg
Trial: 19624299
Drug: IMRT(inv) (inverse-planned
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMRT(inv) (inverse-planned multi-segment solution)
Trial: 11035889
Drug: Pramipexole, 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole, 0.5 mg 3 times per day, with levodopa placebo (n = 151)
Trial: 11035889
Drug: Carbidopa/levodopa, 25/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbidopa/levodopa, 25/100 mg 3 times per day, with pramipexole placebo (n = 150)
Trial: 2062628
Drug: Acellular pertussis
RxNorm normalized name: Acellular pertussis vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acellular pertussis vaccine (ACV) booster at 19 months
Trial: 6825123
Drug: Tricyclic nucleoside
RxNorm normalized name: TRICYCLIC ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tricyclic nucleoside phosphate (iv infusion over 15 minutes once every 3 weeks, doses ranged from 25 to 350 mg/m2)
Trial: 31310929
Drug: Augmented Depression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmented Depression Therapy (ADepT)
Trial: 26077241
Drug: Comparator (progestin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator (progestin or investigator choice chemotherapy)
Trial: 23585665
Drug: canagliflozin 100
RxNorm normalized name: canagliflozin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: canagliflozin 100 mg/d for 8 days
Trial: 24250305
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment intervention
Trial: 22226269
Drug: NovoTwist insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NovoTwist insulin pen needle
Trial: 11412156
Drug: Nefopam (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam (20 mg.4 h‐1)
Trial: 11412156
Drug: Propacetamol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propacetamol (2 g.6 h‐1)
Trial: 11412156
Drug: Morphine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine alone (Control)
Trial: 11412156
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Morphine alone)
Trial: 9524832
Drug: Azithromycin (1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (1,200 mg once weekly)
Trial: 2512804
Drug: Crystalline zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crystalline zinc insulin (CZI) in each liter of TPN solution
Trial: 2512804
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional insulin (control group)
Trial: 31590681
Drug: Internet Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet Cognitive Therapy
Trial: 27897186
Drug: Massage Therapy
RxNorm normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage Therapy (MT) - Swedish massage to upper body
Trial: 23884387
Drug: Beetroot bread
RxNorm normalized name: Eazi-Breed CIDR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beetroot bread (BB) - 200 g containing 100 g beetroot (1.1 mmol nitrate)
Trial: 23884387
Drug: Control white
RxNorm normalized name: SODIUM FLUORIDE 1.1 mg in 1 g DENTAL PASTE, DENTIFRICE [Colgate Tartar Control Whitening Crisp Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control white bread (CB) - 200 g (0 g beetroot, 0.01 mmol nitrate)
Trial: 21642845
Drug: Group-based multidisciplinary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-based multidisciplinary rehabilitation program plus oral medication
Trial: 25546488
Drug: Oral medication
RxNorm normalized name: Oral Medication Syringe 3mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral medication alone
Trial: 16490803
Drug: Telbivudine 600
RxNorm normalized name: telbivudine 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telbivudine 600 mg administered with a high-fat/high-calorie meal
Trial: 16490803
Drug: Telbivudine 600
RxNorm normalized name: telbivudine 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telbivudine 600 mg administered without a high-fat/high-calorie meal (fasting)
Trial: 10353617
Drug: Amifostine pretreatment
RxNorm normalized name: Amifostine
DrugBank: Amifostine (DB01143)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amifostine pretreatment (910 mg/m2)
Trial: 10353617
Drug: Chemotherapy (cisplatin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (cisplatin, adriamycin, cyclophosphamide)
Trial: 1968783
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg esmolol IV
Trial: 1968783
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg esmolol IV
Trial: 1971318
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (amoxicillin and metronidazole with CBS)
Trial: 7395772
Drug: Carnitine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carnitine (0.5 g for 8 weeks, then 1.0 g for 6 weeks)
Trial: 28361826
Drug: Carvedilol (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (12.5 mg once daily for six months)
Trial: 9873217
Drug: Hard water
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hard water (Ca2+ 255 mg/l)
Trial: 9873217
Drug: Soft water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft water (Ca2+ 22 mg/l, Fiuggi water)
Trial: 1848167
Drug: Carbidopa (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbidopa (100 mg)
Trial: 7031872
Drug: 3 daily
RxNorm normalized name: ombitasvir
DrugBank: Ombitasvir (DB09296)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 3 daily doses of 220 mg oral zinc sulfate
Trial: 24946626
Drug: Moxibustion treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxibustion treatment continued for 3 months follow-up.
Trial: 24946626
Drug: Moxibustion treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxibustion treatment before and after treatment comparison.
Trial: 24946626
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received regular hemodialysis and conventional medication without moxibustion.
Trial: 20643988
Drug: Error-free treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Error-free treatment plans in uncomplicated encounters
Trial: 20643988
Drug: Error-free treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Error-free treatment plans in biomedically complicated encounters
Trial: 20643988
Drug: Error-free treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Error-free treatment plans in contextually complicated encounters
Trial: 20643988
Drug: Error-free treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Error-free treatment plans in combined biomedically and contextually complicated encounters
Trial: 15830219
Drug: 0.45 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.45 g/kg alcohol
Trial: 10726009
Drug: Aprosulate 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprosulate 0.5 mg/kg body weight
Trial: 10726009
Drug: Aprosulate 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprosulate 1.0 mg/kg body weight
Trial: 10726009
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (Calciparin 7,500 IU)
Trial: 7734259
Drug: Magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium sulphate 40 mg kg‐1 i.v. pretreatment
Trial: 7038839
Drug: Oral prostaglandin
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prostaglandin E2 (PGE2), 0.33 mg three times daily
Trial: 7038839
Drug: 15(R)15 Me
RxNorm normalized name: LIMOSILACTOBACILLUS FERMENTUM ME-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15(R)15 Me PGE2, 40 micrograms three times daily
Trial: 7038839
Drug: Indomethacin, 50
RxNorm normalized name: Indomethacin, 50 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin, 50 mg three times daily
Trial: 26946614
Drug: Acupuncture-movement therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture-movement therapy (AM)
Trial: 26946614
Drug: Sham acupuncture-movement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham acupuncture-movement therapy (SAM)
Trial: 28778550
Drug: Carbohydrate‐electrolyte solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate‐electrolyte solution (CE)
Trial: 7989943
Drug: Systemic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic chemotherapy for patients with measurable disease
Trial: 7989943
Drug: Systemic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic chemotherapy for patients with assessable disease
Trial: 2692375
Drug: Intraperitoneal cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraperitoneal cisplatin therapy
Trial: 25156082
Drug: Controlled drugs
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled drugs or vehicle
Trial: 22490808
Drug: Step-up infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Step-up infliximab therapy (5 mg/kg body weight, induction regimen of 3 doses at week 0, 2, and 6, maintenance every 8 weeks starting at week 14)
Trial: 22490808
Drug: Top-down infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Top-down infliximab therapy (5 mg/kg body weight, induction regimen of 3 doses at week 0, 2, and 6, maintenance every 8 weeks starting at week 14)
Trial: 22490808
Drug: Step-up infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Step-up infliximab therapy
Trial: 22490808
Drug: Top-down infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Top-down infliximab therapy
Trial: 9133197
Drug: alfentanil 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alfentanil 15 mu g/kg
Trial: 9133197
Drug: alfentanil 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alfentanil 30 mu g/kg
Trial: 9133197
Drug: suxamethonium 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suxamethonium 1.0 mg/kg
Trial: 9133197
Drug: alfentanil 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alfentanil 15 mu g/kg and alfentanil 30 mu g/kg
Trial: 8213541
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg IS-5-MN
Trial: 8213541
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg IS-5-MN
Trial: 8213541
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg IS-5-MN
Trial: 2890369
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg etretin daily
Trial: 2890369
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg etretin daily
Trial: 2890369
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg etretin daily
Trial: 29777950
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU; n=44)
Trial: 16514327
Drug: Lidocaine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (all doses)
Trial: 19250161
Drug: LHA formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LHA formulation (twice a day)
Trial: 16707816
Drug: Placebo (lactose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (lactose tablet) with normal diet for 4 weeks
Trial: 7855219
Drug: Control infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control infusions
Trial: 28238195
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept (5 loading doses every 4 weeks until week 16, then extended to 8 weeks)
Trial: 26554774
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (intravenous fluid until oral diets initiated), n = 19
Trial: 19562622
Drug: Fasting preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting preparation
Trial: 19562622
Drug: Non-fasting preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-fasting preparation
Trial: 19562622
Drug: Fasting preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting preparation (in male patients)
Trial: 17591658
Drug: S-ketamine (moderate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-ketamine (moderate and high doses)
Trial: 17591658
Drug: N,N-dimethyltryptamine (DMT)
DrugBank: Dimethyltryptamine (DB01488)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N,N-dimethyltryptamine (DMT) (moderate and high doses)
Trial: 9444446
Drug: mibefradil 50
RxNorm normalized name: mibefradil 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mibefradil 50 mg QD (titrated to 100 mg if needed)